Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …

Background Polypharmacy may affect outcomes in patients with atrial fibrillation (AF) using
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …

Background The aim of the present meta-analysis was to evaluate the effectiveness and
safety of non-vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists …

Abstract Background and Aim Obesity affects nearly 650 million adults worldwide, and the
prevalence is steadily rising. This condition has significant adverse effects on cardiovascular …

Background: Real-world data show limited utilization of direct oral anticoagulants (DO-ACs)
in obese patients (body mass index [BMI]≥ 30 kg/m2) due to concerns regarding their …

Background: Anticoagulant treatment is used to treat and prevent venous thromboembolism
(VTE). However, the relative effectiveness of newer anticoagulants vs. warfarin has not been …

Background Atrial fibrillation (AF) is an irregular heart rhythm which is becoming more and
more common in this new era. Obesity is a risk factor for cardiovascular events, and obese …

Atrial fibrillation (AF) is a cardiac condition characterized by an irregular heart rhythm, which
is increasingly prevalent in the modern era. All international guidelines strongly advise the …

Objective: The objective of the study was to discuss the controversies surrounding the use
and dosing of direct-acting oral anticoagulants (DOACs) in obese patients recognizing the …

Background: The similar efficacy of rivaroxaban and warfarin in thromboembolic events was
recognized in clinical trials. But there are a few studies about the comparison of these …